Baker Brothers portfolio, Q4 2024
Baker Bros. Advisors · 13F for the quarter ending Dec 31, 2024
For Q4 2024, Baker Bros. Advisors reported $9.4B across 95 US-listed positions, led by INCY (22.7%), ONC (18.8%) and ACAD (8.4%). Compared with its filing for Q3 2024, Baker Brothers opened 9 new positions, added to 20, reduced 4 and sold out of 7; 61 positions did not change.
The largest purchase was an addition to INSM ($40.8M); the largest sale, a reduction of ONC ($191.5M).
Key facts
- 13F portfolio value
- $9.4BQ4 2024
- Positions
- 95
- Largest holding
- INCY 22.7%
- New positions
- 9
- Sold out
- 7
- Filed
- Feb 14, 2025
Holdings as of (Q4 2024), filed with the SEC on . Changes are measured against the filing for Sep 30, 2024. Every tracked investor's Q4 2024 13F.
Bought and sold in Q4 2024
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Beone Medicines LtdONC | ▼ Reduced 9.8% | −1.04M | $191.5M | 2.05% |
| Insmed IncINSM | ▲ Added 13% | +590.95K | $40.8M | 0.44% |
Ionis Pharmaceuticals Incno ticker on file | ▲ New | — | $29.5M | 0.32% |
| Grail IncGRAL | ▲ New | +1.63M | $29.1M | 0.31% |
| Candel Therapeutics IncCADL | ▲ New | +2.98M | $25.9M | 0.28% |
| Bicycle Therapeutics PlcBCYC | ▲ Added 16% | +1.49M | $20.8M | 0.22% |
| CRISPR Therapeutics AGCRSP | ▲ Added 55% | +464.94K | $18.3M | 0.20% |
| Rhythm Pharmaceuticals IncRYTM | ▼ Reduced 4.9% | −314.12K | $17.6M | 0.19% |
| Revolution Medicines IncRVMD | ▲ Added 4.9% | +367.88K | $16.1M | 0.17% |
| Immunovant IncIMVT | ▲ Added 39% | +482.47K | $12M | 0.13% |
| Roivant Sciences LtdROIV | ▲ Added 35% | +969.06K | $11.5M | 0.12% |
| Celcuity IncCELC | ▲ Added 43% | +803.58K | $10.5M | 0.11% |
| Edgewise Therapeutics IncEWTX | ▲ Added 5.4% | +315.88K | $8.4M | 0.09% |
| Vir Biotechnology IncVIR | ▲ New | +1.08M | $8M | 0.09% |
| Intellia Therapeutics IncNTLA | ▲ New | +644.12K | $7.5M | 0.08% |
| Structure Therapeutics IncGPCR | ▲ Added 323% | +276.07K | $7.5M | 0.08% |
Merus N Vno ticker on file | ▲ Added 50% | +150K | $6.3M | 0.07% |
| Immatics N.V.IMTX | ▲ Added 13% | +832.43K | $5.9M | 0.06% |
| Tango Therapeutics IncTNGX | ▼ Sold out | −750K | $5.8M | 0.06% |
Crinetics Pharmaceuticalsno ticker on file | ▼ Sold out | −103.93K | $5.3M | 0.06% |
| BioNTech SEBNTX | ▲ New | +45.03K | $5.1M | 0.05% |
| Neurogene IncNGNE | ▲ Added 48% | +218.44K | $5M | 0.05% |
| Disc Medicine IncIRON | ▲ New | +77.05K | $4.9M | 0.05% |
| Ionis Pharmaceuticals IncIONS | ▲ Added 60% | +134.45K | $4.7M | 0.05% |
| Alector IncALEC | ▼ Sold out | −927.26K | $4.3M | 0.05% |
| Stoke Therapeutics IncSTOK | ▲ Added 6.1% | +265.4K | $2.9M | 0.03% |
| Biomea Fusion IncBMEA | ▼ Reduced 31% | −656.96K | $2.5M | 0.03% |
| KALA BIO IncKALA | ▲ Added 35% | +310.56K | $2.2M | 0.02% |
| Sagimet Biosciences IncSGMT | ▼ Reduced 31% | −428.9K | $1.9M | 0.02% |
| Newamsterdam Pharma CompanyNAMS | ▼ Sold out | −96.71K | $1.6M | 0.02% |
Aerovate Therapeutics Incno ticker on file | ▼ Sold out | −628.94K | $1.3M | 0.01% |
| Rocket Pharmaceuticals IncRCKT | ▲ New | +97.08K | $1.2M | 0.01% |
| Pfizer IncPFE | ▼ Sold out | −35K | $1M | 0.01% |
| PTC Therapeutics IncPTCT | ▲ New | +20.4K | $920.9K | 0.01% |
| Praxis Precision MedicinesPRAX | ▲ Added 2.6% | +8.43K | $648.6K | 0.01% |
| BioCryst Pharmaceuticals IncBCRX | ▼ Sold out | −75.78K | $575.9K | 0.01% |
| Fate Therapeutics IncFATE | ▲ Added 8.7% | +260.63K | $430K | 0.00% |
| Skye Bioscience IncSKYE | ▲ Added 1.1% | +16K | $45.3K | 0.00% |
| Incyte CorpINCY | ▲ Added 0.00% | +446 | $30.8K | 0.00% |
IGM Biosciences Incno ticker on file | ▲ Added 0.05% | +1.99K | $12.2K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte CorpINCY | Health Care | 22.7% | $2.1B | 30.74M | $69.07 | 3+ qtrs | ▲ Added 0.00% |
| 2 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 18.8% | $1.8B | 9.53M | $184.71 | 3+ qtrs | ▼ Reduced 9.8% |
| 3 | Acadia Pharmaceuticals IncACAD | — | 8.41% | $786.8M | 42.88M | $18.35 | 3+ qtrs | No change |
| 4 | Madrigal Pharmaceuticals IncMDGL | Health Care | 6.51% | $609.3M | 1.97M | $308.57 | 3+ qtrs | No change |
| 5 | Summit Therapeutics IncSMMT | Health Care | 4.66% | $435.9M | 24.42M | $17.85 | 3+ qtrs | No change |
| 6 | Revolution Medicines IncRVMD | Health Care | 3.71% | $347.2M | 7.94M | $43.74 | 3+ qtrs | ▲ Added 4.9% |
| 7 | Insmed IncINSM | Health Care | 3.69% | $345.7M | 5.01M | $69.04 | 3+ qtrs | ▲ Added 13% |
| 8 | Rhythm Pharmaceuticals IncRYTM | Health Care | 3.64% | $340.6M | 6.08M | $55.98 | 3+ qtrs | ▼ Reduced 4.9% |
| 9 | Kymera Therapeutics IncKYMR | Health Care | 2.58% | $241.2M | 6M | $40.23 | 3+ qtrs | No change |
| 10 | Kodiak Sciences IncKOD | Health Care | 1.84% | $172.2M | 17.31M | $9.95 | 3+ qtrs | No change |
| 11 | Edgewise Therapeutics IncEWTX | Health Care | 1.76% | $164.4M | 6.16M | $26.70 | 3+ qtrs | ▲ Added 5.4% |
| 12 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 1.63% | $152.4M | 10.89M | $14.00 | 3+ qtrs | ▲ Added 16% |
| 13 | Replimune Group IncREPL | — | 1.43% | $133.8M | 11.05M | $12.11 | 3+ qtrs | No change |
| 14 | Alkermes PLCALKS · SHS | Health Care | 1.29% | $120.3M | 4.18M | $28.76 | 3+ qtrs | No change |
| 15 | Insmed Incno ticker on file · NOTE 0.75% 6/1/2028 | — | 0.99% | $92.9M | — | — | 3+ qtrs | No change |
| 16 | Entrada Therapeutics IncTRDA | — | 0.90% | $84.1M | 4.87M | $17.29 | 3+ qtrs | No change |
| 17 | Abcellera Biologics IncABCL | — | 0.86% | $80.7M | 27.53M | $2.93 | 3+ qtrs | No change |
| 18 | Denali Therapeutics IncDNLI | — | 0.81% | $76.1M | 3.73M | $20.38 | 3+ qtrs | No change |
| 19 | Nurix Therapeutics IncNRIX | — | 0.78% | $73.1M | 3.88M | $18.84 | 3+ qtrs | No change |
| 20 | argenx SEARGX · SPONSORED ADR | Health Care | 0.74% | $68.8M | 111.9K | $615.00 | 3+ qtrs | No change |
| 21 | Ultragenyx PharmaceuticalRARE | — | 0.71% | $66.3M | 1.58M | $42.07 | 3+ qtrs | No change |
| 22 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.60% | $55.7M | 2.82M | $19.78 | 3+ qtrs | No change |
| 23 | Immatics N.V.IMTX · SHS | — | 0.55% | $51.7M | 7.28M | $7.11 | 3+ qtrs | ▲ Added 13% |
| 24 | CRISPR Therapeutics AGCRSP · NAMEN AKT | Health Care | 0.55% | $51.5M | 1.31M | $39.36 | 3+ qtrs | ▲ Added 55% |
| 25 | Stoke Therapeutics IncSTOK | — | 0.55% | $51.1M | 4.63M | $11.03 | 3+ qtrs | ▲ Added 6.1% |
| 26 | Immunocore Holdings plcIMCR · ADS | — | 0.48% | $44.7M | 1.52M | $29.50 | 3+ qtrs | No change |
| 27 | Roivant Sciences LtdROIV · SHS | Health Care | 0.48% | $44.6M | 3.77M | $11.83 | 3+ qtrs | ▲ Added 35% |
| 28 | Sera Prognostics IncSERA · CLASS A COM | — | 0.47% | $44.2M | 5.43M | $8.14 | 3+ qtrs | No change |
| 29 | Immunovant IncIMVT | Health Care | 0.45% | $42.3M | 1.71M | $24.77 | 3+ qtrs | ▲ Added 39% |
| 30 | Xenon Pharmaceuticals IncXENE | — | 0.42% | $39M | 993.68K | $39.20 | 3+ qtrs | No change |
| 31 | Celcuity IncCELC | — | 0.38% | $35.1M | 2.68M | $13.09 | 3+ qtrs | ▲ Added 43% |
| 32 | Monte Rosa Therapeutics IncGLUE | — | 0.36% | $34.1M | 4.92M | $6.94 | 3+ qtrs | No change |
| 33 | Akero Therapeutics Incno ticker on file | — | 0.33% | $30.5M | 1.1M | $27.82 | 3+ qtrs | No change |
| 34 | Cerus CorpCERS | — | 0.32% | $30M | 19.48M | $1.54 | 3+ qtrs | No change |
| 35 | Ionis Pharmaceuticals Incno ticker on file · NOTE 1.75% 6/15/2028 | — | 0.32% | $29.5M | — | — | 1 qtr | New |
| 36 | Grail IncGRAL | Health Care | 0.31% | $29.1M | 1.63M | $17.85 | 1 qtr | New |
| 37 | IDEAYA Biosciences IncIDYA | — | 0.29% | $27.3M | 1.06M | $25.70 | 3+ qtrs | No change |
| 38 | Krystal Biotech IncKRYS | Health Care | 0.28% | $26.6M | 169.93K | $156.66 | 3+ qtrs | No change |
| 39 | Candel Therapeutics IncCADL | — | 0.28% | $25.9M | 2.98M | $8.68 | 1 qtr | New |
| 40 | Praxis Precision MedicinesPRAX | Health Care | 0.27% | $25.5M | 331.53K | $76.96 | 3+ qtrs | ▲ Added 2.6% |
| 41 | IGM Biosciences Incno ticker on file | — | 0.27% | $25M | 4.09M | $6.11 | 3+ qtrs | ▲ Added 0.05% |
| 42 | Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS | — | 0.22% | $20.6M | 1.23M | $16.75 | 3+ qtrs | No change |
| 43 | Merus N Vno ticker on file | — | 0.20% | $18.9M | 450K | $42.05 | 3+ qtrs | ▲ Added 50% |
| 44 | Dyne Therapeutics IncDYN | — | 0.17% | $15.8M | 672.1K | $23.56 | 3+ qtrs | No change |
| 45 | Neurogene IncNGNE | — | 0.17% | $15.4M | 674.45K | $22.86 | 3+ qtrs | ▲ Added 48% |
| 46 | Xencor IncXNCR | — | 0.17% | $15.4M | 670.43K | $22.98 | 3+ qtrs | No change |
| 47 | Bicara Therapeutics IncBCAX | — | 0.16% | $14.5M | 833.33K | $17.42 | 2 qtrs | No change |
| 48 | Prelude Therapeutics IncPRLD | — | 0.14% | $12.9M | 10.12M | $1.28 | 3+ qtrs | No change |
| 49 | Ionis Pharmaceuticals IncIONS | Health Care | 0.13% | $12.5M | 357.92K | $34.96 | 2 qtrs | ▲ Added 60% |
| 50 | Alumis IncALMS | — | 0.13% | $12.3M | 1.56M | $7.86 | 3+ qtrs | No change |
| 51 | Neumora Therapeutics IncNMRA | — | 0.12% | $11M | 1.03M | $10.60 | 3+ qtrs | No change |
| 52 | Design Therapeutics IncDSGN | — | 0.12% | $10.8M | 1.74M | $6.17 | 3+ qtrs | No change |
| 53 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.11% | $9.8M | 361.57K | $27.12 | 2 qtrs | ▲ Added 323% |
| 54 | Verve Therapeutics Incno ticker on file | — | 0.10% | $9.5M | 1.69M | $5.64 | 3+ qtrs | No change |
| 55 | Opthea Limitedno ticker on file · SPONSORED ADS | — | 0.09% | $8.5M | 2.17M | $3.93 | 3+ qtrs | No change |
| 56 | TScan Therapeutics IncTCRX | — | 0.09% | $8.5M | 2.78M | $3.04 | 3+ qtrs | No change |
| 57 | KALA BIO IncKALA | — | 0.09% | $8.3M | 1.2M | $6.94 | 3+ qtrs | ▲ Added 35% |
| 58 | Vir Biotechnology IncVIR | — | 0.09% | $8M | 1.08M | $7.34 | 1 qtr | New |
| 59 | Mirum Pharmaceuticals IncMIRM | Health Care | 0.08% | $7.9M | 190.48K | $41.35 | 3+ qtrs | No change |
| 60 | Arvinas IncARVN | — | 0.08% | $7.8M | 405.58K | $19.17 | 2 qtrs | No change |
| 61 | Intellia Therapeutics IncNTLA | — | 0.08% | $7.5M | 644.12K | $11.66 | 1 qtr | New |
| 62 | 2seventy bio Incno ticker on file | — | 0.08% | $7.3M | 2.5M | $2.94 | 3+ qtrs | No change |
| 63 | Taysha Gene Therapies IncTSHA | — | 0.07% | $6.9M | 4M | $1.73 | 3+ qtrs | No change |
| 64 | Celldex Therapeutics IncCLDX | — | 0.07% | $6.3M | 247.64K | $25.27 | 3+ qtrs | No change |
| 65 | Biomea Fusion IncBMEA | — | 0.06% | $5.6M | 1.45M | $3.88 | 3+ qtrs | ▼ Reduced 31% |
| 66 | Fate Therapeutics IncFATE | — | 0.06% | $5.4M | 3.26M | $1.65 | 3+ qtrs | ▲ Added 8.7% |
| 67 | BioNTech SEBNTX · SPONSORED ADS | Health Care | 0.06% | $5.1M | 45.03K | $113.95 | 1 qtr | New |
| 68 | Disc Medicine IncIRON | — | 0.05% | $4.9M | 77.05K | $63.40 | 1 qtr | New |
| 69 | Relay Therapeutics IncRLAY | — | 0.05% | $4.8M | 1.16M | $4.12 | 3+ qtrs | No change |
| 70 | Contineum Therapeutics IncCTNM · CL A | — | 0.05% | $4.6M | 312.5K | $14.65 | 3+ qtrs | No change |
| 71 | Dbv Technologies S A SponsoredDBVT · SPONSORED ADS | — | 0.05% | $4.5M | 1.46M | $3.09 | 3+ qtrs | — |
| 72 | Sagimet Biosciences IncSGMT | — | 0.05% | $4.3M | 953K | $4.50 | 3+ qtrs | ▼ Reduced 31% |
| 73 | Wave Life Sciences LtdWVE · SHS | — | 0.05% | $4.3M | 344.06K | $12.37 | 2 qtrs | No change |
| 74 | Skye Bioscience IncSKYE | — | 0.04% | $4.1M | 1.45M | $2.83 | 3+ qtrs | ▲ Added 1.1% |
| 75 | Vaxcyte IncPCVX | Health Care | 0.04% | $4M | 48.89K | $81.86 | 3+ qtrs | No change |
| 76 | Sana Biotechnology IncSANA | — | 0.04% | $3.9M | 2.38M | $1.63 | 3+ qtrs | No change |
| 77 | Leap Therapeutics Incno ticker on file | — | 0.04% | $3.4M | 1.17M | $2.87 | 3+ qtrs | No change |
| 78 | Aligos Therapeutics IncALGS | — | 0.04% | $3.3M | 83.06K | $39.84 | 3+ qtrs | No change |
| 79 | Prime Medicine IncPRME | — | 0.03% | $3M | 1.03M | $2.92 | 3+ qtrs | No change |
| 80 | Protara Therapeutics IncTARA | — | 0.03% | $2.8M | 536.83K | $5.28 | 3+ qtrs | No change |
| 81 | Enliven Therapeutics IncELVN | — | 0.03% | $2.6M | 114.83K | $22.50 | 3+ qtrs | No change |
| 82 | Arcturus Therapeutics HoldingsARCT | — | 0.03% | $2.6M | 151.33K | $16.97 | 3+ qtrs | No change |
| 83 | Compass Therapeutics IncCMPX | — | 0.02% | $2.3M | 1.56M | $1.45 | 3+ qtrs | No change |
| 84 | Generation Bio Cono ticker on file | — | 0.02% | $2.1M | 1.94M | $1.06 | 3+ qtrs | No change |
| 85 | HOOKIPA Pharma Incno ticker on file | — | 0.02% | $1.6M | 812.81K | $2.01 | 3+ qtrs | No change |
| 86 | Mersana Therapeutics Incno ticker on file | — | 0.02% | $1.6M | 1.09M | $1.43 | 3+ qtrs | No change |
| 87 | vTv Therapeutics IncVTVT · CL A | — | 0.01% | $1.3M | 97.31K | $13.81 | 3+ qtrs | No change |
| 88 | Rocket Pharmaceuticals IncRCKT | — | 0.01% | $1.2M | 97.08K | $12.57 | 1 qtr | New |
| 89 | PTC Therapeutics IncPTCT | Health Care | 0.01% | $920.9K | 20.4K | $45.14 | 1 qtr | New |
| 90 | Century Therapeutics IncIPSC | — | 0.01% | $805.4K | 797.46K | $1.01 | 3+ qtrs | No change |
| 91 | PMV Pharmaceuticals IncPMVP | — | 0.01% | $486.3K | 322.02K | $1.51 | 3+ qtrs | No change |
| 92 | Acrivon Therapeutics IncACRV | — | 0.00% | $318.4K | 52.89K | $6.02 | 3+ qtrs | No change |
| 93 | Foghorn Therapeutics IncFHTX | — | 0.00% | $212.5K | 45.03K | $4.72 | 3+ qtrs | No change |
| 94 | Tyra Biosciences IncTYRA | — | 0.00% | $147.4K | 10.61K | $13.90 | 3+ qtrs | No change |
| 95 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $17.8K | 833.33K | $0.0214 | 3+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 75.1% | $7B | 24 |
| No sector on file | 24.9% | $2.3B | 71 |
Questions and answers
What did Baker Brothers own in Q4 2024?
Baker Bros. Advisors's 13F for Q4 2024 lists 95 positions worth $9.4B. The largest: INCY (22.7%), ONC (18.8%), ACAD (8.4%), MDGL (6.5%), SMMT (4.7%).
What did Baker Brothers buy in Q4 2024?
The largest purchases, by the shares bought at the quarter-end price the filing implies: INSM (added, $40.8M), Ionis Pharmaceuticals Inc (new, $29.5M), GRAL (new, $29.1M), CADL (new, $25.9M), BCYC (added, $20.8M), CRSP (added, $18.3M).
What did Baker Brothers sell in Q4 2024?
The largest sales: ONC (reduced, $191.5M), RYTM (reduced, $17.6M), TNGX (sold out, $5.8M), Crinetics Pharmaceuticals (sold out, $5.3M), ALEC (sold out, $4.3M), BMEA (reduced, $2.5M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Dec 31, 2024 on Feb 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q4 2024: Baker Bros. Advisors 13F holdings”, data as of 14 February 2025. https://funkfolio.com/gurus/baker-brothers/2024-q4
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Dec 31, 2024.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Dec 31, 2024, filed Feb 14, 2025. Changes compare share counts with the filing for Sep 30, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9.4B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 3 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.